[go: up one dir, main page]

WO2001047505A3 - Verwendung von azolen zur prävention von hautkrebs - Google Patents

Verwendung von azolen zur prävention von hautkrebs Download PDF

Info

Publication number
WO2001047505A3
WO2001047505A3 PCT/EP2000/012595 EP0012595W WO0147505A3 WO 2001047505 A3 WO2001047505 A3 WO 2001047505A3 EP 0012595 W EP0012595 W EP 0012595W WO 0147505 A3 WO0147505 A3 WO 0147505A3
Authority
WO
WIPO (PCT)
Prior art keywords
azoles
skin cancer
preventing skin
preventing
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/012595
Other languages
English (en)
French (fr)
Other versions
WO2001047505A2 (de
Inventor
Bernward Fladung
Harald Enzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to BR0017046-1A priority Critical patent/BR0017046A/pt
Priority to AT00983295T priority patent/ATE303146T1/de
Priority to EP00983295A priority patent/EP1244445B1/de
Priority to JP2001548100A priority patent/JP2003518490A/ja
Priority to CA002395345A priority patent/CA2395345A1/en
Priority to NZ519731A priority patent/NZ519731A/en
Priority to DE50011084T priority patent/DE50011084D1/de
Priority to MXPA02006247A priority patent/MXPA02006247A/es
Priority to AU20085/01A priority patent/AU778835B2/en
Publication of WO2001047505A2 publication Critical patent/WO2001047505A2/de
Publication of WO2001047505A3 publication Critical patent/WO2001047505A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Azole eignen sich für die Prävention von Strahlen-induziertem Hautkrebs.
PCT/EP2000/012595 1999-12-24 2000-12-12 Verwendung von azolen zur prävention von hautkrebs Ceased WO2001047505A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR0017046-1A BR0017046A (pt) 1999-12-24 2000-12-12 Uso de azóis para prevenção de câncer de pele
AT00983295T ATE303146T1 (de) 1999-12-24 2000-12-12 Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
EP00983295A EP1244445B1 (de) 1999-12-24 2000-12-12 Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
JP2001548100A JP2003518490A (ja) 1999-12-24 2000-12-12 皮膚癌予防のためのアゾールの使用
CA002395345A CA2395345A1 (en) 1999-12-24 2000-12-12 Use of azoles for preventing skin cancer
NZ519731A NZ519731A (en) 1999-12-24 2000-12-12 Use of azoles for preventing radiation induced skin cancer
DE50011084T DE50011084D1 (de) 1999-12-24 2000-12-12 Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
MXPA02006247A MXPA02006247A (es) 1999-12-24 2000-12-12 Uso de azoles para la prevencion del cancer de piel.
AU20085/01A AU778835B2 (en) 1999-12-24 2000-12-12 Use of azoles for preventing skin cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19963052.6 1999-12-24
DE19963052A DE19963052A1 (de) 1999-12-24 1999-12-24 Verwendung von Azolen zur Prävention von Hautkrebs

Publications (2)

Publication Number Publication Date
WO2001047505A2 WO2001047505A2 (de) 2001-07-05
WO2001047505A3 true WO2001047505A3 (de) 2002-06-20

Family

ID=7934530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/012595 Ceased WO2001047505A2 (de) 1999-12-24 2000-12-12 Verwendung von azolen zur prävention von hautkrebs

Country Status (16)

Country Link
US (1) US20020193384A1 (de)
EP (1) EP1244445B1 (de)
JP (1) JP2003518490A (de)
AR (1) AR027088A1 (de)
AT (1) ATE303146T1 (de)
AU (1) AU778835B2 (de)
BR (1) BR0017046A (de)
CA (1) CA2395345A1 (de)
CO (1) CO5251436A1 (de)
DE (2) DE19963052A1 (de)
DK (1) DK1244445T3 (de)
ES (1) ES2246912T3 (de)
GT (1) GT200000218A (de)
MX (1) MXPA02006247A (de)
NZ (1) NZ519731A (de)
WO (1) WO2001047505A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
AU2006283040B2 (en) * 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP1895012A1 (de) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Methode zur Induktion von Tumorapoptose durch Erhöhung des Stickstoffoxidniveaus
EP2753179A4 (de) 2011-09-09 2015-03-04 Univ Leland Stanford Junior Topische itraconazol-formulierungen und ihre verwendung
WO2018115319A2 (en) * 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
CN110917192A (zh) * 2018-09-20 2020-03-27 华东师范大学 咪康唑在制备抗肿瘤药物中的应用
CN114948947B (zh) * 2021-12-31 2023-12-29 广州医科大学附属第五医院 硝酸芬替康唑在制备抗肿瘤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
WO1999026611A1 (en) * 1997-11-20 1999-06-03 President And Fellows Of Harvard College Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US5998394A (en) * 1996-04-05 1999-12-07 Voorhees; John J. Compositions for treating skin conditions by enhancing the activity of 1,25(OH)2 D3 using an RXR ligand and/or a 24-hydroxylase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648010A1 (de) * 1996-11-20 1998-05-28 Haarmann & Reimer Gmbh Verwendung von substituierten Benzazolen als UV-Absorber, neue Benzazole und Verfahren zu ihrer Herstellung
US5864393A (en) * 1997-07-30 1999-01-26 Brown University Research Foundation Optical method for the determination of stress in thin films
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
US6108087A (en) * 1998-02-24 2000-08-22 Kla-Tencor Corporation Non-contact system for measuring film thickness

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5998394A (en) * 1996-04-05 1999-12-07 Voorhees; John J. Compositions for treating skin conditions by enhancing the activity of 1,25(OH)2 D3 using an RXR ligand and/or a 24-hydroxylase inhibitor
WO1999026611A1 (en) * 1997-11-20 1999-06-03 President And Fellows Of Harvard College Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KHALID M HUMAYUN ET AL: "Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro.", JOURNAL OF NEUROSURGERY, vol. 90, no. 5, May 1999 (1999-05-01), pages 918 - 927, XP001033555, ISSN: 0022-3085 *
MUKHTAR H ET AL: "CLOTRIMAZOLE AN INHIBITOR OF EPIDERMAL BENZO-A-PYRENE METABOLISM AND DNA BINDING AND CARCINOGENICITY OF THE HYDROCARBON", CANCER RESEARCH, vol. 44, no. 10, 1984, pages 4233 - 4240, XP001033544, ISSN: 0008-5472 *
PAUL C ET AL: "CHROMOBLASTOMYCOSIS WITH MALIGNANT TRANSFORMATION AND CUTANEOUS-SYNOVIAL SECONDARY LOCALIZATION THE POTENTIAL THERAPEUTIC ROLE OF ITRACONAZOLE", JOURNAL OF MEDICAL AND VETERINARY MYCOLOGY, vol. 29, no. 5, 1991, pages 313 - 316, XP001033552, ISSN: 0268-1218 *
VANUYTSEL L ET AL: "KETOCONAZOLE THERAPY FOR ADVANCED PROSTATIC CANCER FEASIBILITY AND TREATMENT RESULTS", JOURNAL OF UROLOGY, vol. 137, no. 5, 1987, pages 905 - 908, XP001033554, ISSN: 0022-5347 *

Also Published As

Publication number Publication date
EP1244445B1 (de) 2005-08-31
DE19963052A1 (de) 2001-06-28
MXPA02006247A (es) 2003-01-28
GT200000218A (es) 2002-06-13
JP2003518490A (ja) 2003-06-10
CO5251436A1 (es) 2003-02-28
CA2395345A1 (en) 2001-07-05
EP1244445A2 (de) 2002-10-02
DK1244445T3 (da) 2005-11-07
AU778835B2 (en) 2004-12-23
DE50011084D1 (de) 2005-10-06
US20020193384A1 (en) 2002-12-19
ATE303146T1 (de) 2005-09-15
NZ519731A (en) 2004-06-25
WO2001047505A2 (de) 2001-07-05
AR027088A1 (es) 2003-03-12
AU2008501A (en) 2001-07-09
BR0017046A (pt) 2002-11-05
ES2246912T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
ZA200202461B (en) Compounds for the treatment of ischemia.
AU2935200A (en) Compounds for the treatment of obesity
EP1176964B8 (de) Verwendungen von et743 zur behandlung von krebs
AU2001272852A1 (en) Composition for the treatment of migraine
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ZA200003236B (en) Combination therapy for the treatment of migraine.
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
CA2362698A1 (en) Resorcinol derivatives
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
WO2001047505A3 (de) Verwendung von azolen zur prävention von hautkrebs
AU7363000A (en) Method for reducing the risk of cancer
AU2021601A (en) Composition for the treatment of dandruff
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
AU2001275107A1 (en) Vitamin d3 analogs as radiosensitizers for the treatment of cancer
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
AU2001285156A1 (en) Combination therapy for the treatment of migraine
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
ZA200203166B (en) Treatment of cancer.
AU5552400A (en) Treatment of cancer
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200003235B (en) Combination therapy for the treatment of migraine.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000983295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10149169

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 548100

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20085/01

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006247

Country of ref document: MX

Ref document number: 2395345

Country of ref document: CA

Ref document number: 519731

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2000983295

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 519731

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519731

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 20085/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000983295

Country of ref document: EP